NexGel, Inc. develops and commercializes healthcare, beauty and over-the-counter products built around high-water-content hydrogel technology for healthcare and consumer applications.
Company news commonly covers operating and financial results, hydrogel and biomaterial product activity, strategic partnerships, acquisition and licensing activity, financing arrangements, and governance changes. Recent updates also document the launch of BioNX Surgical following a completed license and asset acquisition of commercial-stage regenerative biomaterial products.
NEXGEL (NASDAQ: NXGL) closed the license and acquisition of Celularity's commercial-stage regenerative biomaterials portfolio and launched BioNX Surgical. The deal is led by a $5.5 million strategic investment from Sequence LifeScience™ and financed via a convertible note with a $0.60 conversion price and 50% warrant coverage. The transaction is expected to approximately triple pro-forma annual revenue to about $35 million and be immediately accretive to profitability, adding 6 established products with existing reimbursement and accelerating commercialization.
NEXGEL (NASDAQ:NXGL) moved its shareholder update conference call to April 21, 2026 at 4:30 P.M. ET to discuss the Celularity transaction. Investors can join via U.S. toll-free 1-800-267-6316, international 1-203-518-9783, or the company webcast under Events and Presentations.
NEXGEL (NASDAQ:NXGL) rescheduled its shareholder update conference call to April 23, 2026 at 4:30 P.M. ET to provide an update on the proposed transaction with Celularity.
The company said it will not finance the transaction under its previously announced Securities Purchase Agreement and is negotiating a new financing with a different investor group; additional details are expected on April 23.
Call details include U.S. toll-free 1-800-267-6316, international 1-203-518-9783, and a webcast via Events and Presentations.
NEXGEL (NASDAQ:NXGL) rescheduled its shareholder update conference call to April 15, 2026 at 4:30 P.M. ET to provide an update on the proposed Celularity transaction. The company said there is no assurance the transaction will close and it will not use the previously announced Securities Purchase Agreement financing.
The company is negotiating a new financing structure with a different group of investors and expects to provide additional transaction details on the April 15 call. Call and webcast access information has been provided for shareholders.
NEXGEL (NASDAQ:NXGL) rescheduled its fourth quarter and full-year 2025 financial results conference call to April 8, 2026 at 4:30 P.M. ET to allow more time to provide shareholders detail on its previously announced proposed transaction with Celularity.
The company filed its Form 10-K for year ended December 31, 2025 with the SEC on March 31, 2026. Call dial-in numbers and a webcast will be available for investors.
NEXGEL (NASDAQ:NXGL) announced it will report fourth quarter and full year 2025 financial results after market close on March 31, 2026. Management will host a conference call at 4:30 P.M. ET the same day and provide a live webcast and replay.
Dial-in numbers, replay access code 11161124, and a 90-day archived webcast will be available for investors and analysts.
NEXGEL (NASDAQ: NXGL) announced terms to license and acquire a portfolio of six commercial-stage regenerative biomaterial products from Celularity (NASDAQ: CELU).
Key terms: $15 million upfront cash plus up to $20 million in milestone payments tied to net sales. The company says the deal should roughly triple revenue to ~ $35 million and make NEXGEL immediately profitable upon closing. The portfolio targets tendon repair, skin grafts, and bone growth, includes decade-long clinical use and reimbursement pathways, adds commercial/scientific staff, and remains subject to customary closing and financing.
NEXGEL (NASDAQ: NXGL) signed a definitive agreement to license and acquire a portfolio of six commercial-stage regenerative biomaterial products from Celularity, a deal expected to approximately triple NEXGEL’s annual revenue to about $35 million and make the company immediately profitable upon closing.
The portfolio includes established products with existing insurance reimbursement, plans for three 510(k) filings in 2026–2028, and an experienced commercial team expected to join. The company anticipates approximately $14.9 million of additional financing in Q1 or early Q2 2026; closing remains subject to customary closing processes and financing.
NEXGEL (NASDAQ:NXGL) announced financing of $1.797 million related to a potential acquisition targeted to close in the first quarter of 2026. The transaction is subject to mutual due diligence and other conditions, and funds will be returned to the investor if the acquisition is not consummated. The investor may provide a potential additional $14.869 million pending completion of full due diligence. Palladium Capital Group acted as placement agent. The company said it will provide further details to shareholders during Q1 2026.
NEXGEL (NASDAQ:NXGL) announced that its previously disclosed spin-off, NexGelRx, received strategic investments from Eric Gruntfest and Ariel Imas of Diesis Holdings, LLC on Dec 16, 2025. In connection with the investment, NexGelRx appointed Eric Gruntfest as a board observer and strategic advisor.
Mr. Gruntfest brings over 20 years of experience in reimbursement strategy, payer solutions, and patient access, and currently serves as Managing Partner at Diesis Holdings and CEO of RMBB Health; his background includes senior roles at Medtronic, MiMedx, Shire, and Celgene. Management said his expertise will support commercialization and patient access for NexGelRx’s ultra-gentle hydrogel transdermal delivery products.